Financial Performance - Operating revenue for the reporting period was ¥513,356,547.37, a decrease of 6.16% year-on-year[7] - Net profit attributable to shareholders of the listed company was ¥53,508,543.51, representing a growth of 21.23% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥48,392,200.16, up 16.78% year-on-year[7] - Basic earnings per share increased by 7.20% to ¥0.1146[7] - The company's operating profit for Q3 2020 was approximately ¥78.70 million, an increase of 21.3% compared to ¥64.86 million in the same period last year[42] - Net profit for Q3 2020 reached ¥69.06 million, up 18.3% from ¥58.39 million in Q3 2019[42] - The total comprehensive income for Q3 2020 was ¥69.06 million, compared to ¥58.39 million in the same quarter last year, marking a growth of 18.3%[43] - The total profit for the third quarter was CNY 173.13 million, an increase of 41.3% compared to CNY 122.49 million in the same period last year[49] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,591,859,517.46, an increase of 1.63% compared to the end of the previous year[7] - The company's total liabilities decreased to CNY 1,472,348,019.32 from CNY 1,789,323,009.37, indicating a reduction of approximately 17.7%[35] - Total assets as of September 30, 2020, amounted to CNY 4,591,859,517.46, compared to CNY 4,518,083,187.45 at the end of 2019[35] - Total liabilities reached CNY 1,789,323,009.37, with current liabilities at CNY 1,115,075,326.87 and non-current liabilities at CNY 674,247,682.50[64] - The total liabilities to equity ratio stands at approximately 0.66, indicating a balanced capital structure[65] Cash Flow - The net cash flow from operating activities was ¥91,209,626.94, an increase of 28.73% compared to the same period last year[7] - Cash generated from operating activities decreased by 13.12% to ¥212,996,495.85, due to increased cash payments for goods and services[16] - The cash inflow from operating activities amounted to CNY 1,366,513,180.76, an increase from CNY 1,205,116,055.13 in the previous period, representing a growth of approximately 13.36%[56] - The cash outflow for purchasing goods and services was CNY 697,391,667.96, compared to CNY 531,501,094.97, reflecting an increase of approximately 31.23%[56] - The net cash flow from financing activities was -CNY 21,206,077.71, an improvement from -CNY 661,373,167.20, indicating a positive change of about 96.80%[57] Investments - Long-term equity investments increased by 297.97% to ¥9,164,870.30, primarily due to additional investments in subsidiaries[15] - Investment income surged by 488.52% to ¥4,506,326.97, mainly from the disposal of equity in a subsidiary[16] - The company reported a significant increase in long-term equity investments, rising to CNY 9.16 million from CNY 2.30 million at the end of 2019[33] Shareholder Information - Net assets attributable to shareholders of the listed company increased by 15.56% to ¥2,848,798,397.64[7] - The total number of ordinary shareholders at the end of the reporting period was 29,159[11] - The company's cash dividend policy was strictly followed, with a total cash dividend distribution of CNY 26.39 million for the year 2019, amounting to CNY 0.60 per 10 shares[23] Regulatory and Compliance - The company received government subsidies amounting to ¥32,333,922.47 during the reporting period[8] - The company’s board approved the termination of a previous private placement plan due to regulatory changes[17] - The company received approval from the China Securities Regulatory Commission for the registration of a stock issuance to specific investors on October 12, 2020[21] - The company implemented the new revenue recognition standard starting January 1, 2020, affecting the classification of contract liabilities[70] Research and Development - Research and development expenses for the quarter were CNY 30,786,921.36, up from CNY 28,861,888.10 in the previous period[41] - The company's R&D expenses for Q3 2020 were ¥8.25 million, up from ¥7.28 million in Q3 2019, indicating a focus on innovation[45] - Research and development expenses increased to CNY 21.55 million, up 26.3% from CNY 17.05 million in the previous year[51]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥917,554,527.33, representing a 7.30% increase compared to ¥855,153,191.41 in the same period last year [21]. - The net profit attributable to shareholders increased by 77.60% to ¥69,512,111.84, up from ¥39,140,342.05 in the previous year [21]. - The net profit after deducting non-recurring gains and losses rose by 112.72% to ¥50,865,689.57, compared to ¥23,912,179.25 in the same period last year [21]. - The basic earnings per share increased by 62.68% to ¥0.1565, up from ¥0.0962 in the previous year [21]. - The total assets at the end of the reporting period were ¥4,580,515,828.06, a 1.38% increase from ¥4,518,083,187.45 at the end of the previous year [21]. - The net assets attributable to shareholders increased by 11.73% to ¥2,754,363,704.30, compared to ¥2,465,213,969.38 at the end of the previous year [21]. - The net cash flow from operating activities decreased by 30.13% to ¥121,786,868.91, down from ¥174,305,595.85 in the same period last year [21]. - Financial expenses decreased by 38.31% year-on-year, indicating improved efficiency in fund utilization [37]. - Operating cash flow decreased by 30.13% to CNY 121.79 million, primarily due to increased payments for intermediate procurement [73]. - The company maintained a cash and cash equivalents net increase of CNY 19.05 million, a 102.99% improvement compared to the previous year [74]. Investment and Projects - The company has multiple ongoing investment projects in steroid hormone APIs, biological enzyme preparations, and functional feed additives, supported by national policies and strong market demand [6]. - The company has a project for an annual production of 1,200 tons of steroid drugs, with a total investment of CNY 69,636 million [88]. - The company has a project for an annual production of 2,770.96 tons of biological enzyme preparations, with a total investment of CNY 78,333 million [88]. - The company invested ¥312.32 million in the GMP construction project for steroid hormones, fully funded by raised capital [86]. - The total amount of raised funds is CNY 137,112.24 million [90]. - The total amount of raised funds invested during the reporting period is CNY 5,941.71 million [90]. - The cumulative amount of raised funds invested is CNY 113,251.75 million [90]. - The company plans to allocate 9,100 million from the fundraising to new projects, including 3,000 million for a veterinary drug workshop and 4,000 million for GMP renovation [96]. - The company aims to enhance its market position through strategic acquisitions and expansions in the biotechnology sector [96]. Market Strategy and Trends - The company plans to continue monitoring macroeconomic trends and adjust market strategies accordingly due to global trade tensions and the COVID-19 pandemic [7]. - The company is facing investment risks due to macroeconomic fluctuations and increased industry competition, which may impact the expected returns from ongoing projects [113]. - The global trade tensions and COVID-19 pandemic have introduced uncertainties, prompting the company to adjust its market strategies and product structures accordingly [113]. - The company has established long-term business relationships with over 500 enterprises globally, providing high-quality products and services [112]. - The company is actively expanding its market presence, with over 80% of its sales coming from international markets, including the USA, Japan, India, and Germany [111]. Environmental Compliance and Management - The company has established a wastewater treatment plant with a daily capacity of 4,000 tons, ensuring all pollutants are discharged within standards [152]. - The company has a contract for hazardous waste treatment, with daily collection and transfer to qualified disposal companies, maintaining compliance with environmental regulations [151]. - The company has implemented regular maintenance for air pollution control facilities, with no instances of exceeding emission standards reported [154]. - The company has achieved a desulfurization efficiency of 96% and a dust removal efficiency of 99% through its flue gas treatment systems [157]. - The company has a comprehensive environmental management system in place, with third-party verification for wastewater and air quality monitoring [156]. - The company has received multiple environmental impact assessments and approvals for its construction projects, ensuring compliance with regulatory requirements [159]. Corporate Governance and Shareholder Information - The company will not distribute cash dividends or issue bonus shares for this reporting period [8]. - The company has not engaged in entrusted financial management, derivative investments, or entrusted loans during the reporting period, indicating a conservative financial strategy [102][103][104]. - The company did not engage in any repurchase agreements during the reporting period, reflecting a conservative approach to capital management [195]. - The report indicates that there are no preferred shares outstanding, simplifying the capital structure [199]. - The company has a stable management team with an average industry experience of over 19 years, which supports its rapid development [60]. - The total number of common stock shareholders at the end of the reporting period was 23,269 [192]. Research and Development - Research and development investment increased by 18.00% to CNY 51.96 million, driven by higher intangible asset amortization expenses [73]. - The company has completed the registration of 11 products in the biopharmaceutical sector, including 5 domestically and 6 internationally [69]. - The company is strongly focused on the research and development of steroid hormone intermediates and raw materials, with leading capabilities in biotechnological fermentation and chemical synthesis [111]. Operational Efficiency - The company has implemented a market-oriented "production based on sales" model to enhance operational efficiency [35]. - The company has strengthened internal governance and optimized production processes to reduce product costs [37]. - The company has established a detailed supplier evaluation process to ensure the quality of raw material procurement [34].

Financial Performance - Total revenue for Q1 2020 reached ¥402,535,465, an increase of 17.94% compared to ¥341,308,608 in the same period last year[8] - Net profit attributable to shareholders was ¥18,746,963, a significant turnaround from a loss of ¥18,154,900 in the previous year, representing a growth of 203.25%[8] - Net profit excluding non-recurring items was ¥13,088,046, compared to a loss of ¥21,131,641, marking an increase of 161.94%[8] - Basic earnings per share increased to ¥0.0426 from a loss of ¥0.0446, reflecting a growth of 195.52%[8] - The company reported a total comprehensive income of CNY 16,921,427.93 for Q1 2020, compared to a comprehensive loss of CNY 18,916,308.81 in the previous period[44] Cash Flow - Net cash flow from operating activities was ¥29,369,882, a substantial improvement of 587.79% from a negative cash flow of ¥6,021,009[8] - The net cash flow from financing activities was ¥155.47 million yuan, an increase of 151.35% year-on-year, mainly due to increased bank borrowings[17] - Cash inflow from operating activities amounted to ¥361,067,109.34, an increase from ¥269,187,713.73 in the previous period[50] - The net cash flow from financing activities was ¥155,472,762.26, compared to a negative cash flow of ¥302,794,354.12 in the previous period[52] - The net cash flow from investing activities was -¥43,598,895.66, an improvement from -¥197,055,860.25 in the previous period[51] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,746,030,010.79, up 5.05% from ¥4,518,083,187.45 at the end of the previous year[8] - Total liabilities increased to CNY 1,878,277,336.85 from CNY 1,789,323,009.37, which is an increase of approximately 5.0%[35] - The company's equity attributable to shareholders rose to CNY 2,599,667,087.41 from CNY 2,465,213,969.38, representing an increase of about 5.4%[36] - Short-term borrowings at the end of the period increased by 266.74 million yuan, a growth of 53.24%, mainly due to an increase in short-term bank loans[16] - The company's total assets as of Q1 2020 were CNY 2,948,160,454.03, an increase from CNY 2,797,074,739.65 in the previous period[42] Government Subsidies and Other Income - The company received government subsidies amounting to ¥7,465,988 during the reporting period[9] - The company received government subsidies that increased other income by 4.16 million yuan, a growth of 125.64% year-on-year[16] Operational Challenges and Adjustments - The company faces potential uncertainties in future operating performance due to the ongoing impact of the COVID-19 pandemic and disruptions in the global supply chain[20] - The company is adjusting its product structure to address the impact of African swine fever and is increasing marketing efforts in overseas markets[20] Investment and Fundraising - The total amount of raised funds for the quarter is 137,112.24 million, with a cumulative investment of 110,372.42 million[24] - The company adjusted the investment amount for the "New Hormone GMP Construction Project" from 400 million yuan to 309 million yuan, reducing the total fundraising amount by 91 million yuan, which accounts for 17.5% of the total fundraising[26] - The company plans to allocate the reduced fundraising of 91 million yuan to new projects, including 30 million yuan for the construction of a veterinary drug workshop at Hunan Chengda Biotechnology Co., 40 million yuan for GMP renovation at Henan Lihua Pharmaceutical Co., and 21 million yuan for acquiring 70% equity in Hunan Longteng Biotechnology Co.[26] Compliance and Management - The company has no violations regarding external guarantees during the reporting period[28] - There are no non-operating fund occupations by controlling shareholders or their related parties during the reporting period[29] - The company has conducted strict budget management to control procurement costs and reduce project implementation expenses, maximizing the efficiency of fundraising usage[27]

Financial Performance - The company's operating revenue for 2019 was CNY 2,048,133,404.03, representing a 15.83% increase compared to CNY 1,768,167,808.17 in 2018[15]. - The net profit attributable to shareholders for 2019 was CNY 127,522,059.24, up 12.35% from CNY 113,508,486.63 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was CNY 98,113,603.76, a significant increase of 98.84% compared to CNY 49,342,337.16 in 2018[15]. - The net cash flow from operating activities reached CNY 442,165,361.20, marking a 116.80% increase from CNY 203,948,204.25 in 2018[15]. - The total assets at the end of 2019 were CNY 4,518,083,187.45, a decrease of 5.90% from CNY 4,801,120,582.60 in 2018[15]. - The net assets attributable to shareholders increased by 15.09% to CNY 2,465,213,969.38 from CNY 2,142,005,405.16 in 2018[15]. - The basic earnings per share for 2019 were CNY 0.3054, reflecting a 9.42% increase from CNY 0.2791 in 2018[15]. - The diluted earnings per share were CNY 0.3009, up 7.81% from CNY 0.2791 in the previous year[15]. - The weighted average return on equity was 5.63%, slightly down from 5.72% in 2018[15]. - The company proposed a cash dividend of CNY 0.6 per 10 shares, based on a total share capital of 439,841,924 shares as of December 31, 2019[5]. Revenue Breakdown - Total revenue for the year reached approximately 2.048 billion yuan, with a quarterly breakdown showing Q1 at 341.31 million yuan, Q2 at 513.84 million yuan, Q3 at 547.08 million yuan, and Q4 at 645.90 million yuan[18]. - The net profit attributable to shareholders for the year was approximately 44.25 million yuan in Q4, following a loss of 18.15 million yuan in Q1[18]. - The net cash flow from operating activities for the year was positive, with Q4 generating 197.01 million yuan, significantly improving from a negative cash flow of 6.02 million yuan in Q1[18]. - Revenue from the biopharmaceutical sector accounted for 58.93% of total revenue, with a year-on-year increase of 9.13%[54]. - Revenue from the bioproducts sector represented 24.89% of total revenue, showing a slight increase of 0.55% year-on-year[54]. - The biomanufacturing sector saw a significant growth of 278.31%, contributing CNY 114.54 million to total revenue[54]. - The company's revenue from steroid hormone raw materials reached ¥1,206,896,724.09, accounting for 58.93% of total revenue, with a year-on-year growth of 9.13%[55]. - Revenue from functional feed additives surged to ¥114,540,690.34, representing 5.59% of total revenue, with a remarkable year-on-year increase of 278.31%[55]. Market and Product Development - The company focuses on the research, production, and sales of biological enzyme preparations, steroid hormone raw materials, and functional feed additives, indicating a diverse product portfolio[25]. - The biological enzyme products include feed enzymes, energy enzymes, food enzymes, and environmental enzymes, which are essential for various industrial applications[26]. - The steroid hormone raw materials primarily serve respiratory and immune system medications, with key products including prednisone and dexamethasone[27]. - The company aims to replace antibiotics in animal feed with its functional feed additives, which have shown effectiveness in promoting growth and reducing diarrhea rates in livestock[28]. - The company is focusing on optimizing production processes and reducing product costs to enhance operational efficiency[30]. - The company is positioned to benefit from the increasing industry concentration as smaller firms exit the market due to product homogenization[32]. - The company has expanded its enzyme product categories from feed enzymes to energy, food, paper, textile, and environmental enzymes, indicating a broad market strategy[37]. - The company is focusing on developing new products, including a fermentation-based progesterone product, which is expected to become a key offering[68]. - The company is advancing the development of antibiotic alternatives through the expression systems of glucose oxidase and related functional enzymes, contributing to new profit growth points[70]. Research and Development - The company has developed 4 proprietary technologies and holds 174 invention patents, showcasing its strong innovation capabilities[41]. - Research and development expenses increased by 23.02% from 90.75 million to 111.64 million, reflecting the company's commitment to innovation[67]. - R&D investment in 2019 amounted to ¥111,640,772.97, representing 5.45% of total revenue, with a 19.75% increase in R&D personnel to 394[71]. - The company has ongoing projects aimed at optimizing production processes, with expected cost reductions of 5% to 10% for various steroid hormone intermediates[68]. Financial Management and Investments - Financial expenses decreased by 13.99% year-on-year, improving the efficiency of capital utilization[30]. - The company has seen a 76.88% decrease in cash funds year-on-year, primarily due to loan repayments and investments in various projects[39]. - Long-term equity investments decreased by 42.2% year-on-year, attributed to the subsidiary Victory Enzymes GmbH being in the product registration phase[39]. - The company’s investment activities saw a net cash outflow increase of 214.62%, primarily due to investments in new projects and acquisitions[52]. - The company’s cash and cash equivalents decreased by 203.39% year-on-year, attributed to reduced financing inflows and increased project investments[52]. - The company has a total of 10 million CNY in loans secured by land use rights and buildings, with a loan term from January 28, 2019, to January 27, 2021[168]. - The company has provided guarantees for loans totaling 70 million CNY from Industrial and Commercial Bank of China and 30 million CNY from China Bank, among others[166]. Environmental Compliance - The company is classified as a key pollutant discharge unit, with specific emissions monitored and reported[184]. - The company has successfully maintained compliance with environmental standards, with no instances of exceeding discharge limits reported[184]. - The company has established a wastewater treatment plant with a daily processing capacity of 4,000 tons, ensuring all pollutants are discharged within standards[191]. - The company has equipped emergency response resources including micro fire stations, fire pipelines, protective eyewear, gloves, gas masks, fire sand, and extinguishers[190]. - The company has conducted environmental impact assessments for all new projects and obtained relevant environmental approvals[198]. Shareholder Relations - The company has implemented a cash dividend policy, distributing RMB 0.60 per share to shareholders, totaling RMB 24,405,322.00 for the 2018 fiscal year[121]. - The cash dividend represents 20.69% of the net profit attributable to shareholders for 2019[125]. - The company has maintained a consistent cash dividend policy over the past three years[125]. - The company’s cash dividend policy aligns with the guidelines from the China Securities Regulatory Commission[123]. - The company has ensured that minority shareholders have had the opportunity to express their opinions and that their rights are protected[122]. Strategic Outlook - The company plans to leverage the market opportunities for alternative feed additives, aiming to become a leading enterprise in functional feed additives in China[38]. - The company is committed to improving its operational efficiency and financial management through enhanced collaboration and resource integration[117]. - The company is exploring potential mergers and acquisitions to strengthen its market position[188]. - The company aims to enhance its international presence and expand market share in the biological enzyme preparation sector[37].

广东溢多利生物科技股份有限公司 2019 年第三季度报告全文 广东溢多利生物科技股份有限公司 2019 年第三季度报告 2019-089 2019 年 10 月 1 广东溢多利生物科技股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈少美、主管会计工作负责人李著及会计机构负责人(会计主管 人员)朴希春声明：保证季度报告中财务报表的真实、准确、完整。 2 | | 本报告期末 | 上年度末 | | 本报告期末比上年度 | | --- | --- | --- | --- | --- | | | | | | 末增减 | | | | 调整前 | 调整后 | 调整后 | | 总资产（元） | 4,557,677,610.60 | 4,801,120,582.60 | 4,801,120,582.60 | -5.07% | | 归属于上市公司股东的净资产 （元） | 2,355,240,949.66 | ...

Financial Performance - Operating revenue for the reporting period was CNY 547,080,607.96, representing a year-on-year increase of 21.24%[8] - Net profit attributable to shareholders was CNY 44,136,222.67, an increase of 2.48% year-on-year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 69.95% to CNY 41,438,942.06 compared to the same period last year[8] - The net profit for the period was CNY 107,582,245.37, an increase of 11.37% from CNY 96,600,227.75 year-on-year, driven by the performance of the subsidiary, increased sales in the feed enzyme segment, and reduced interest expenses[21] - Total operating revenue for Q3 2019 was CNY 547,080,607.96, an increase of 21.3% compared to CNY 451,223,197.37 in Q3 2018[42] - Net profit for Q3 2019 reached CNY 58,391,655.24, representing a 12.4% increase from CNY 51,929,066.85 in Q3 2018[43] - The net profit for Q3 2019 reached CNY 3,869,484.12, a significant recovery from a net loss of CNY 7,916,320.44 in Q3 2018[46] - The total comprehensive income attributable to the parent company was CNY 44,136,222.67, compared to CNY 43,068,027.30 in the same period last year[46] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was CNY 245,159,458.95, up 145.42%[8] - Cash flow from operating activities increased significantly to CNY 245,159,458.95, a 145.42% rise from CNY 99,893,884.00 in the previous year, attributed to increased accounts payable and the use of bank acceptance bills for payments[21] - The company's cash and cash equivalents decreased by CNY 711,553,168.29, a decline of 1875.79% compared to an increase of CNY 40,069,637.24 in the previous year, primarily due to repayments of bank loans and investments in various projects[21] - The company's cash and cash equivalents decreased to CNY 90,895,789.33 from CNY 715,330,476.34, indicating a significant reduction in liquidity[38] - The total cash inflow from operating activities was CNY 1,205,116,055.13, compared to CNY 1,137,893,513.33 in the previous year, reflecting an increase of 5.9%[58] - In Q3 2019, the company's operating cash flow net amount was -241,741,112.39 CNY, a significant decline compared to 66,504,849.49 CNY in the previous year[62] - Total cash and cash equivalents at the end of Q3 2019 were 161,718,143.63 CNY, down from 228,149,914.24 CNY in the same period last year, reflecting a decrease of approximately 29.2%[59] Assets and Liabilities - Total assets at the end of the reporting period decreased by 5.07% to CNY 4,557,677,610.60 compared to the end of the previous year[8] - The company's current assets decreased to ¥2,128,445,580.34 from ¥2,587,033,976.05 at the end of 2018, indicating a decline of approximately 17.7%[32] - Total liabilities decreased to ¥1,930,236,940.41 from ¥2,394,425,839.26, a reduction of approximately 19.4%[34] - The company's total equity attributable to shareholders increased to ¥2,355,240,949.66 from ¥2,142,005,405.16, marking a growth of about 9.9%[35] - Total liabilities amounted to CNY 2,394,425,839.26, with current liabilities at CNY 1,442,576,384.69 and non-current liabilities at CNY 951,849,454.57[68] - The company’s total assets as of the end of Q3 2019 were 4,801,120,582.60 CNY, remaining stable compared to the previous year[66] Investments and Expenditures - The company is actively investing in new projects, including a CNY 120 million investment in a new steroid hormone GMP project and a CNY 150 million investment in a food-grade enzyme project[21] - The company reported a significant increase in investment income, which rose to CNY 48,870,201.00 from CNY 23,055,760.35, representing a growth of 111.3%[54] - The company reported a net cash outflow from investment activities of 296,054,984.19 CNY, compared to a net outflow of 154,894,196.33 CNY in the previous year, indicating an increase in investment expenditures[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 429,325,611[12] - The company has implemented its first employee stock ownership plan, involving 170 employees, to enhance employee engagement and retention[22] - The first phase of the employee stock ownership plan was released from restrictions on July 19, 2019, with a total of 9,941,000 shares held, accounting for 2.32% of the company's total share capital[24] - The number of participants in the first phase of the employee stock ownership plan decreased from 162 to 158 due to resignations[24] Research and Development - The company reported a significant increase in research and development expenses, which rose to CNY 28,861,888.10 from CNY 20,022,946.57, marking a 44.1% increase[42] - Research and development expenses increased to CNY 7,284,711.34, up 38.4% from CNY 5,264,517.90 in the previous year[46] - Research and development expenses increased to CNY 17,052,434.85, up from CNY 13,556,031.39, marking a rise of 25.0% year-over-year[54] Regulatory and Compliance - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[28] - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[74] - The company implemented new financial instrument standards starting January 1, 2019, impacting the classification and measurement of financial instruments[68]

Financial Performance - Operating revenue for the reporting period was CNY 547,080,607.96, representing a 21.24% increase year-on-year[8]. - Net profit attributable to shareholders was CNY 44,136,222.67, a 2.48% increase compared to the same period last year[8]. - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 69.95% to CNY 41,438,942.06[8]. - Basic earnings per share for the reporting period was CNY 0.1069, a 0.94% increase year-on-year[8]. - The company's operating revenue for the year-to-date reached ¥1,402,233,799.37, representing a 13.08% increase compared to ¥1,240,055,722.52 in the same period last year[21]. - Net profit for the period was ¥107,582,245.37, reflecting an 11.37% increase from ¥96,600,227.75 year-on-year, driven by improved performance in the feed enzyme segment and reduced interest expenses[21]. - The total operating income for the year-to-date period reached CNY 1,402,233,799.37, an increase of 13.1% from CNY 1,240,055,722.52 in the previous year[48]. - The net profit for the year-to-date period was CNY 107,582,245.37, compared to CNY 96,600,227.75 in the same period last year, reflecting a growth of 11.5%[50]. Cash Flow - Cash flow from operating activities for the year-to-date was CNY 245,159,458.95, an increase of 145.42%[8]. - Cash flow from operating activities increased significantly to ¥245,159,458.95, a 145.42% rise from ¥99,893,884.00 in the previous year, attributed to increased accounts payable and the use of bank acceptance bills for payments[21]. - The cash flow from operating activities generated a net amount of ¥245,159,458.95, compared to ¥99,893,884.00 in the previous year, indicating a growth of 145.0%[58]. - The net cash flow from operating activities was -241,741,112.39 CNY, compared to 66,504,849.49 CNY in the previous period, indicating a significant decline in operational cash generation[62]. Assets and Liabilities - Total assets at the end of the reporting period decreased by 5.07% to CNY 4,557,677,610.60 compared to the end of the previous year[8]. - The company's cash and cash equivalents decreased significantly to CNY 214,123,056.41 from CNY 938,479,567.55, indicating a decline of approximately 77%[32]. - Total liabilities decreased to CNY 741,783,477.46 from CNY 1,194,951,600.78, a reduction of 37.9%[39]. - The company's total liabilities decreased to CNY 1,930,236,940.41 from CNY 2,394,425,839.26, indicating a decline of approximately 19.4%[34]. - Total current liabilities decreased to CNY 1,198,620,545.03 from CNY 1,442,576,384.69, a reduction of about 16.9%[34]. Shareholder Information - The company reported a total of 13,472 common shareholders at the end of the reporting period[12]. - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., held 32.99% of the shares, amounting to 141,615,094 shares[12]. - The equity attributable to the owners of the parent company increased to CNY 2,355,240,949.66 from CNY 2,142,005,405.16, showing a growth of about 9.9%[35]. Research and Development - The company reported a significant increase in research and development expenses, which rose to CNY 28,861,888.10 from CNY 20,022,946.57, marking a 44.1% increase[42]. - Research and development expenses increased to CNY 7,284,711.34, up 38.4% from CNY 5,264,517.90 in the previous year[46]. - Research and development expenses increased to ¥17,052,434.85, up from ¥13,556,031.39, representing a rise of 25.0% year-over-year[54]. Investment Activities - The company’s investment activities generated a cash outflow of ¥296,054,984.19, a 91.13% increase from the previous year, driven by investments in various production projects[21]. - The company reported an investment income of ¥48,870,201.00, which is a substantial increase from ¥23,055,760.35 in the previous year, reflecting a growth of 111.3%[54]. Operational Costs - The company reported a 14.42% increase in operating costs, totaling ¥906,743,805.10, in line with the growth in operating revenue[21]. - Total operating costs for Q3 2019 were CNY 485,812,379.92, up from CNY 415,687,483.92 in the same period last year, reflecting a growth of 16.8%[42]. - The total operating costs for the year-to-date period were CNY 1,291,478,408.83, up from CNY 1,158,317,411.30 in the previous year[48].

Financial Performance - Total revenue for the first half of 2019 reached ¥855,153,191.41, an increase of 8.41% compared to the same period last year[18]. - Net profit attributable to shareholders was ¥39,140,342.05, representing a growth of 24.92% year-on-year[18]. - Basic earnings per share increased by 24.94% to ¥0.0962[18]. - The company reported a total non-operating income of ¥15,228,162.80, after accounting for government subsidies of ¥20,631,827.91 and other non-operating expenses[22]. - The company achieved a consolidated revenue of RMB 855.15 million in the first half of 2019, representing an 8.41% increase year-over-year[41]. - The net profit attributable to shareholders was RMB 39.14 million, reflecting a 24.92% growth compared to the same period last year[41]. - The gross margin for feed enzyme products was 61.96%, up 4.34% from the previous year, indicating strong profitability in this segment[49]. - The company reported a net profit of -2,918,098.02 yuan from its main subsidiaries, indicating a loss[81]. - The total comprehensive income for the first half of 2019 was CNY 66,438,847.99, compared to CNY 19,690,146.41 in the previous year, indicating a growth of 236.56%[179]. Cash Flow and Investments - Net cash flow from operating activities surged by 509.01% to ¥174,305,595.85[18]. - Cash and cash equivalents decreased by 68.95% compared to the beginning of the year, primarily due to repayment of bank loans and increased investments in construction projects[30]. - Investment activities resulted in a net cash outflow of ¥-218,405,753.59, a 42.75% increase in outflow compared to ¥-152,994,704.46, primarily due to investments in new projects[46]. - Financing activities showed a significant net cash outflow of ¥-592,303,563.66, a decrease of 443.28% from the previous year, mainly due to early loan repayments[46]. - The cash inflow from operating activities was CNY 726,474,362.18, a decrease from CNY 792,195,417.39 in the first half of 2018[180]. - The cash flow from investment activities resulted in a net outflow of CNY 72,865,089.45, compared to a smaller outflow of CNY 600,158.71 in the first half of 2018[186]. Assets and Liabilities - Total assets decreased by 8.11% to ¥4,411,961,523.62 compared to the end of the previous year[18]. - Cash and cash equivalents decreased to 291.42 million RMB from 938.48 million RMB[162]. - The company's total assets reached CNY 2,112,900,000.00, indicating a robust asset base[194]. - Total liabilities decreased to CNY 906,534,773.21 from CNY 1,194,951,600.78, a reduction of 24.1%[169]. - The company's total equity at the end of the reporting period was CNY 1,857,279,360.92, showing a growth from CNY 1,810,015,298.24 at the beginning of the year[198]. Research and Development - The company has established a comprehensive R&D system with over 300 R&D personnel, including more than 100 with doctoral or master's degrees[33]. - Research and development expenses increased by 6.65% to ¥44,030,536.64 from ¥41,284,592.86, attributed to investments in new technologies by subsidiaries[45]. - The company has developed a unique technology for producing steroid hormones from plant sterols, significantly reducing production costs and environmental impact[34]. - The company’s subsidiary, Hunan Xinheng Biotechnology Co., is a leader in the research and production of steroid hormone intermediates and raw materials, with a strong capability for industrialization of research outcomes[84]. Market Strategy and Product Development - The company plans to adjust its product structure to mitigate risks from the ongoing African swine fever outbreak[5]. - The company focuses on the development, production, and sales of biopharmaceuticals, biological enzyme preparations, plant extracts, and functional feed additives[25]. - The company has accelerated its deployment in the "antibiotic-free" sector, launching a combination of medicinal plants and biological enzyme preparations[42]. - The company plans to continue expanding its product offerings and investing in new technologies to enhance market competitiveness[45]. - The company is actively adjusting its product structure to mitigate risks from livestock diseases, particularly the ongoing impact of African swine fever, by shifting focus towards poultry, aquaculture, and ruminants[87]. Shareholder and Equity Information - The company has a total of 10 major shareholders, with no significant changes in their holdings during the reporting period[143]. - The company reported a profit distribution of CNY 4,770 million to shareholders, which is a decrease of 41.08% compared to the previous year[189]. - The employee stock ownership plan involved 170 employees, with a total subscription amount of 200.94 million RMB at a price of 11.16 RMB per share, and the lock-up period is from July 18, 2016, to July 17, 2019[101]. - The company has not experienced any major litigation or arbitration matters during the reporting period[97]. Compliance and Governance - The semi-annual financial report has not been audited[95]. - The company has established an environmental protection management system and complies with national and local environmental regulations, ensuring effective operation of environmental protection facilities[122]. - The company did not engage in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[76][77][78].

Financial Performance - Total revenue for Q1 2019 was CNY 341,308,608.77, an increase of 1.62% compared to CNY 335,864,495.95 in the same period last year[8]. - Net profit attributable to shareholders was a loss of CNY 18,154,900.29, a decrease of 257.36% from a profit of CNY 11,537,529.35 in the previous year[8]. - Net cash flow from operating activities was a negative CNY 6,021,009.36, down 132.64% from CNY 18,447,243.30 in the same period last year[8]. - The company reported a basic and diluted earnings per share of CNY -0.0446, compared to CNY 0.0284 in the same period last year, a decrease of 257.04%[8]. - The weighted average return on equity was -0.85%, down 1.44% from 0.59% in the previous year[8]. - The net profit for Q1 2019 was a loss of CNY 18.92 million, compared to a profit of CNY 20.78 million in Q1 2018, indicating a significant decline in profitability[50]. - The company reported a gross profit margin of approximately -5.88% in Q1 2019, compared to a positive margin in Q1 2018, indicating a decline in operational efficiency[50]. Assets and Liabilities - Total assets increased by 8.18% to CNY 4,382,095,149.86 from CNY 4,050,592,097.70 at the end of the previous year[8]. - The company's total assets decreased to CNY 2.74 billion as of March 31, 2019, down from CNY 3.00 billion at the end of 2018, reflecting a reduction of approximately 8.79%[47]. - The company's current assets decreased to CNY 2,091,854,674.53 from CNY 2,587,033,976.05, representing a reduction of about 19.2%[40]. - Total liabilities decreased to CNY 1,994,316,715.44 from CNY 2,394,425,839.26, a decline of about 16.7%[41]. - The company's equity attributable to shareholders decreased from CNY 2,142,005,405.16 to CNY 2,125,398,842.69, a decrease of approximately 0.8%[42]. Shareholder Information - The company had a total of 13,650 common shareholders at the end of the reporting period[12]. - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., held 34.82% of the shares, totaling 141,615,094 shares[12]. Cash Flow and Financing - Cash and cash equivalents decreased by 51,924.88 million yuan, a decline of 55.33%, primarily due to loan repayments and investment in fundraising projects[18]. - The total cash outflow from financing activities was CNY 502,794,354.12, compared to CNY 203,118,008.20 in the previous period, indicating a significant increase in cash outflows[59]. - The company reported a decrease in cash inflow from operating activities, totaling CNY 269,187,713.73, down from CNY 436,664,805.80 in the previous period, a decline of approximately 38.4%[58]. - The company incurred financial expenses of CNY 11,501,968.26, which is significantly higher than CNY 6,940,475.89 in the previous period, marking an increase of approximately 65.7%[53]. Research and Development - The company has initiated several R&D projects and filed patents for new technologies, including glucose oxidase and phytase[26]. - Research and development expenses increased to CNY 21.55 million in Q1 2019, up from CNY 18.33 million in Q1 2018, representing a growth of about 17.93%[48]. - Research and development expenses rose to CNY 5,885,897.68 from CNY 3,355,061.03, reflecting an increase of about 75.1%[53]. Market and Product Strategy - The company plans to launch new products and enhance marketing efforts in response to the impact of African swine fever on the feed enzyme product structure[25]. - The outbreak of African swine fever since August 2018 poses significant risks to the livestock industry, prompting the company to adjust its product structure and increase marketing efforts for poultry, ruminants, and aquatic animal feed enzymes[28]. - The company is focusing on expanding its product offerings in response to market changes, particularly in the enzyme feed sector[28]. Investment Projects - The company has multiple ongoing investment projects in biomedicine, enzyme preparations, and functional feed additives, with a total fundraising amount of approximately 137,239.59 million CNY, of which 9,215.73 million CNY was invested in the current quarter[31]. - The cumulative amount of raised funds utilized is 76,842.87 million CNY, with a cumulative change in use amounting to 9,100 million CNY, representing 6.63% of the total[31]. - The company completed the issuance of convertible bonds, significantly alleviating financial pressure and ensuring smooth progress of fundraising projects[27]. Operational Challenges - The company is facing investment risks due to macroeconomic changes and industry competition, and plans to accelerate project construction to mitigate these risks[28]. - The company has reported a significant impact from livestock disease outbreaks on its upstream feed and feed additive sectors[28]. - The company reported a net profit warning for the upcoming reporting period, indicating potential losses or significant changes compared to the same period last year[35].

Financial Performance - The company's operating revenue for 2018 was CNY 1,768,167,808.17, representing a 17.94% increase compared to CNY 1,499,263,322.64 in 2017[18] - The net profit attributable to shareholders for 2018 was CNY 113,508,486.63, a 41.14% increase from CNY 80,424,345.71 in 2017[18] - The net cash flow from operating activities reached CNY 203,948,204.25, a significant increase of 4,765.15% compared to a negative cash flow of CNY -4,371,739.71 in 2017[18] - The total assets of the company at the end of 2018 were CNY 4,801,120,582.60, marking a 24.86% increase from CNY 3,845,271,645.91 at the end of 2017[18] - The net assets attributable to shareholders increased by 10.49% to CNY 2,142,005,405.16 at the end of 2018, up from CNY 1,938,648,669.32 in 2017[18] - The basic earnings per share for 2018 were CNY 0.2791, reflecting a 41.17% increase from CNY 0.1977 in 2017[18] - Total revenue for the year reached approximately 1.67 billion yuan, with a quarterly breakdown of 335.86 million yuan in Q1, 452.97 million yuan in Q2, 451.22 million yuan in Q3, and 528.11 million yuan in Q4[20] - Net profit attributable to shareholders was approximately 113.07 million yuan for the year, with Q1 at 11.54 million yuan, Q2 at 19.80 million yuan, Q3 at 43.07 million yuan, and Q4 at 39.11 million yuan[20] Investment and Expansion Plans - The company plans to expand its investment projects in biomedicine and enzyme preparations, supported by strong market demand and favorable national policies[6] - The company has proposed a cash dividend of CNY 0.60 per 10 shares, with no bonus shares issued[7] - The company aims to expand its product lines in biological enzyme preparations, microbial preparations, and functional feed additives[37] - The company is focused on extending its industrial chain in the specialty biopharmaceutical sector and promoting green manufacturing and environmental remediation technologies[37] - The company has established a joint venture in Germany to strengthen its market presence in Europe[50] - The company is constructing a biopharmaceutical industrial park in Jinshi City, which is progressing as planned to enhance its production capabilities[116] Research and Development - The company is focused on the development and production of biopharmaceuticals, enzyme preparations, and functional feed additives, indicating a strong commitment to innovation in biotechnology[29] - The company has a robust R&D team with over 100 personnel holding doctoral or master's degrees, and core technical staff with over 19 years of experience[41] - The company’s R&D center has been recognized as a national enterprise technology center, enhancing its core competitiveness[41] - The company is focusing on research and development in enzyme preparations and related technologies[87] - The company has achieved industrialization for several key projects, including the production of progesterone intermediates and mometasone furoate intermediates, which are expected to enhance product competitiveness[69] Market Trends and Challenges - The company is facing risks from the African swine fever outbreak, which has impacted the livestock industry and related feed additive sectors[7] - The biopharmaceutical sector has seen significant revenue growth due to advancements in gene engineering and microbial fermentation technologies, enhancing the company's competitive edge[33] - The enzyme preparation industry is expected to maintain rapid growth, driven by increasing demand from downstream industries such as biofuels, environmental protection, and animal feed[35] - The steroid hormone drug market has been growing at an annual rate of 10% to 15%, with China's steroid hormone raw material production accounting for approximately one-third of the global total[34] Financial Management and Cash Flow - The company reported a 338.67% increase in cash and cash equivalents, primarily due to funds raised from the public issuance of convertible bonds and improved collection of accounts receivable[39] - The company achieved a net cash flow from operating activities increase of 4,765.15%, attributed to improved collection of accounts receivable and government subsidies received[52] - The total cash inflow from financing activities was CNY 2,080,115,462.06, up 109.03% from the previous year[73] - The company received government subsidies amounting to 26.26 million yuan, impacting the cash flow statement significantly[21] Corporate Governance and Compliance - The company has established measures to prevent conflicts of interest and ensure compliance with market regulations[134] - The company is committed to avoiding any illegal occupation of assets and ensuring fair market practices in related transactions[134] - The company has ongoing commitments regarding non-competition and related transactions, which are being adhered to[134] - The company reported no significant litigation or arbitration matters during the reporting period[167] Employee and Social Responsibility - Employee training programs are in place, including onboarding, job-specific, and skill enhancement training, to improve employee quality[196] - The company actively engages in social responsibility, ensuring shareholder rights protection and maintaining transparency through various communication channels[195] - The company has implemented a stable profit distribution policy to provide reasonable returns to shareholders[195]